ProCE Banner Activity

AML Current Treatment Strategies and Paradigms Ahead: Expert Discussion of Frequently Asked Questions

Clinical Thought

In this commentary, expert faculty address audience questions from a live symposium on current and emerging AML treatment strategies.

Released: January 24, 2023

Expiration: January 23, 2024

No longer available for credit.

Share

Faculty

Daniel Pollyea

Daniel Pollyea, MD, MS

Professor of Medicine
Clinical Director of Leukemia Services
Associate Chief of Clinical Affairs
Robert H. Allen MD Chair in Hematology Research
Division of Hematology
University of Colorado School of Medicine
Aurora, Colorado

Courtney DiNardo

Courtney DiNardo, MD, MSCE

Professor of Medicine
Department of Leukemia
MD Anderson Cancer Center
Houston, Texas

Eytan M. Stein

Eytan M. Stein, MD

Chief, Leukemia Service
Director, Program for Drug Development in Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

ProCE Banner

Supporters

Astellas Text

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Servier Pharmaceuticals

Syndax

Partners

Clinical Care Options, LLC

ProCE Banner

Program Director Disclosure

Program Director

Daniel Pollyea, MD, MS

Professor of Medicine
Clinical Director of Leukemia Services
Associate Chief of Clinical Affairs
Robert H. Allen MD Chair in Hematology Research
Division of Hematology
University of Colorado School of Medicine
Aurora, Colorado

Daniel Pollyea, MD, MS: consultant/advisor/speaker: AbbVie, Arcellx, AstraZeneca, BeiGene, BerGen Bio, Bristol-Myers Squibb, Genentech, Hibercell, Immunogen, Jazz, Kura, LINK, Magenta, Medivir, Novartis, Qihan, Ryvu, Syros, Zentalis; researcher: AbbVie, Bristol-Myers Squibb, Karyopharm, Teva; data and safety monitoring board: Aptevo, Glycomimetics.

Faculty Disclosure

Primary Author

Courtney DiNardo, MD, MSCE

Professor of Medicine
Department of Leukemia
MD Anderson Cancer Center
Houston, Texas

Courtney DiNardo, MD, MSCE: consultant/advisor/speaker: AbbVie, Bristol-Myers Squibb, Daiichi Sankyo, Genmab, GlaxoSmithKline, Immunogen, Novartis, Notable Labs, Servier, Stemline, Takeda; researcher (paid to institution): AbbVie, Astex, BeiGene, Cleave, ImmuneOnc, Loxo.

Eytan M. Stein, MD

Chief, Leukemia Service
Director, Program for Drug Development in Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York

Eytan M. Stein, MD: consultant/advisor/speaker: AbbVie, Agios, Aptose, Astellas, Blueprint, Bristol Myers Squibb, Calithera, CTI Biopharma, Daiichi Sankyo, Foghorn, Genentech, Genesis, Gilead Sciences, Janssen, Jazz Pharmaceuticals, Kura, Menarini, Neoleukin, Novartis, OnCusp, Ono Pharma, PinotBio, Servier, Syndax, Syros; data and safety monitoring board: Cellectis, Epizyme; researcher: Bristol Myers Squibb, Eisai; stock/stock options: Auron.